Tyche Wealth Partners LLC Buys Shares of 2,249 STERIS plc (NYSE:STE)

Tyche Wealth Partners LLC acquired a new position in STERIS plc (NYSE:STE - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 2,249 shares of the medical equipment provider's stock, valued at approximately $462,000.

Other institutional investors also recently bought and sold shares of the company. Bleakley Financial Group LLC boosted its holdings in STERIS by 8.7% during the 3rd quarter. Bleakley Financial Group LLC now owns 1,680 shares of the medical equipment provider's stock valued at $407,000 after acquiring an additional 134 shares during the period. Franklin Resources Inc. boosted its holdings in STERIS by 171.2% during the 3rd quarter. Franklin Resources Inc. now owns 838,569 shares of the medical equipment provider's stock valued at $191,370,000 after acquiring an additional 529,308 shares during the period. Assetmark Inc. boosted its holdings in STERIS by 24.6% during the 3rd quarter. Assetmark Inc. now owns 13,410 shares of the medical equipment provider's stock valued at $3,252,000 after acquiring an additional 2,647 shares during the period. KBC Group NV boosted its holdings in STERIS by 52.0% during the 3rd quarter. KBC Group NV now owns 12,071 shares of the medical equipment provider's stock valued at $2,928,000 after acquiring an additional 4,132 shares during the period. Finally, Wilmington Savings Fund Society FSB purchased a new stake in STERIS during the 3rd quarter valued at about $9,949,000. 94.69% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at STERIS

In related news, SVP Cary L. Majors sold 1,682 shares of the firm's stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $217.32, for a total transaction of $365,532.24. Following the completion of the transaction, the senior vice president now owns 11,372 shares of the company's stock, valued at $2,471,363.04. This trade represents a 12.88 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.14% of the company's stock.

STERIS Stock Up 0.3 %

Shares of NYSE:STE traded up $0.65 during trading on Monday, hitting $223.88. The stock had a trading volume of 194,139 shares, compared to its average volume of 506,213. STERIS plc has a 12 month low of $197.82 and a 12 month high of $248.24. The company has a market capitalization of $22.10 billion, a PE ratio of 47.52 and a beta of 0.84. The firm's fifty day moving average is $212.57 and its 200 day moving average is $224.51. The company has a quick ratio of 1.55, a current ratio of 2.13 and a debt-to-equity ratio of 0.32.

STERIS (NYSE:STE - Get Free Report) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.33 by ($0.01). STERIS had a return on equity of 13.91% and a net margin of 8.66%. Analysts anticipate that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, March 21st. Stockholders of record on Thursday, February 20th will be given a $0.57 dividend. This represents a $2.28 annualized dividend and a dividend yield of 1.02%. The ex-dividend date is Thursday, February 20th. STERIS's dividend payout ratio is currently 48.41%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Needham & Company LLC restated a "hold" rating on shares of STERIS in a report on Friday, November 8th. StockNews.com lowered STERIS from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, October 29th. Piper Sandler upped their price target on STERIS from $260.00 to $265.00 and gave the company an "overweight" rating in a research report on Monday, February 3rd. JMP Securities reaffirmed a "market outperform" rating and set a $265.00 price target on shares of STERIS in a research report on Thursday. Finally, Stephens reaffirmed an "overweight" rating and set a $240.00 price target on shares of STERIS in a research report on Thursday. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, STERIS has an average rating of "Moderate Buy" and an average target price of $258.75.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.